Mattia Arrigo1, Nicolas Vodovar2, Seraina Von Moos3, Elisabeth Masson4, Stephan Segerer3,5, Pietro E Cippà3,6, Alexandre Mebazaa2,7. 1. Department of Cardiology, University Hospital Zurich, Zurich, Switzerland. 2. INSERM, UMR-S 942, Paris, France. 3. Department of Nephrology, University Hospital Zurich, Zurich, Switzerland. 4. Department of Biochemistry, Lariboisère University Hospital, Paris, France. 5. Department of Nephrology, Kantonsspital Aarau, Aarau, Switzerland. 6. Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA. 7. Department of Anesthesiology and Critical Care Medicine, St. Louis and Lariboisère University Hospitals, Paris, France.
Abstract
BACKGROUND: Novel multiplex assays allow the simultaneous identification of a large number of plasma proteins. While these new technologies have been shown to be highly sensitive and accurate for the identification of plasma proteins, the use of this technology to quantify those proteins has not been properly investigated. In this pilot study, we tested the accuracy of the proximity extension assay (PEA) for the quantification of the cardiac biomarker brain natriuretic peptide (BNP) compared to a standard clinically approved method. METHODS: Concentrations of BNP were assessed in 120 plasma samples from 30 patients with PEA and compared to chemiluminescent microparticle immunoassay (CMIA). Venous blood samples were collected from in tubes containing ethylenediaminetetraacetic acid, centrifuged within 6 hours at 3,500 rpm for 15 minutes at 4°C, frozen and stored at -80°C until analyzed. Correlation between the CMIA and PEA techniques was tested using the Spearman's rank correlation coefficient (rho) and the agreement was described with a Bland-Altman plot. RESULTS: Brain natriuretic peptide values obtained by CMIA and PEA were highly correlated (Spearman's rho = 0.865, P < .0001). In two patients, PEA consistently overestimated resp. underestimated BNP values compared to CMIA. After removal of those two patients, a very high correlation between the two techniques was shown (rho = 0.966, P < .0001). A high agreement between the two techniques over the whole range of tested concentrations was shown. CONCLUSION: This pilot study showed for the first time an excellent correlation between a clinically approved method and the PEA-based approach for quantification of circulating plasma BNP.
BACKGROUND: Novel multiplex assays allow the simultaneous identification of a large number of plasma proteins. While these new technologies have been shown to be highly sensitive and accurate for the identification of plasma proteins, the use of this technology to quantify those proteins has not been properly investigated. In this pilot study, we tested the accuracy of the proximity extension assay (PEA) for the quantification of the cardiac biomarker brain natriuretic peptide (BNP) compared to a standard clinically approved method. METHODS: Concentrations of BNP were assessed in 120 plasma samples from 30 patients with PEA and compared to chemiluminescent microparticle immunoassay (CMIA). Venous blood samples were collected from in tubes containing ethylenediaminetetraacetic acid, centrifuged within 6 hours at 3,500 rpm for 15 minutes at 4°C, frozen and stored at -80°C until analyzed. Correlation between the CMIA and PEA techniques was tested using the Spearman's rank correlation coefficient (rho) and the agreement was described with a Bland-Altman plot. RESULTS:Brain natriuretic peptide values obtained by CMIA and PEA were highly correlated (Spearman's rho = 0.865, P < .0001). In two patients, PEA consistently overestimated resp. underestimated BNP values compared to CMIA. After removal of those two patients, a very high correlation between the two techniques was shown (rho = 0.966, P < .0001). A high agreement between the two techniques over the whole range of tested concentrations was shown. CONCLUSION: This pilot study showed for the first time an excellent correlation between a clinically approved method and the PEA-based approach for quantification of circulating plasma BNP.
Authors: Mattia Arrigo; Nicolas Vodovar; Seraina Von Moos; Elisabeth Masson; Stephan Segerer; Pietro E Cippà; Alexandre Mebazaa Journal: J Clin Lab Anal Date: 2018-05-23 Impact factor: 2.352
Authors: Astrid Monfort; Kelly Da Silva; Nicolas Vodovar; Etienne Gayat; Alain Cohen-Solal; Philippe Manivet Journal: Biomark Med Date: 2015-11-19 Impact factor: 2.851
Authors: Mattia Arrigo; Nicolas Vodovar; Seraina Von Moos; Elisabeth Masson; Stephan Segerer; Pietro E Cippà; Alexandre Mebazaa Journal: J Clin Lab Anal Date: 2018-05-23 Impact factor: 2.352
Authors: Becky C Carlyle; Robert R Kitchen; Zoe Mattingly; Amanda M Celia; Bianca A Trombetta; Sudeshna Das; Bradley T Hyman; Pia Kivisäkk; Steven E Arnold Journal: Front Neurol Date: 2022-06-06 Impact factor: 4.086